**MAP-AMR Year 1 PPS and Retrospective Candida data**

**Table 1\_Patient interview form (PPS)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **KNH (n=112)** | **NSIRH (n=9)** | **TNH (n=40)** | **Total (n=161)** |
| **Median age in years (min, max)** | Median\_ 0.4 yrs  Min\_1 day  Max\_78.5 yrs | Median\_ 38.4 yrs  Min\_18.5 yrs  Max\_67.5 yrs | Median\_46.1 yrs  Min\_1 day  Max\_ 82.2 yrs | **Median\_15.0 yrs**  **Min\_ 1 day**  **Max\_ 82.2 yrs** |
| **Age categories** |  |  |  |  |
| Neonates (0-28 days) | 41 | 0 | 7 | 48 |
| % | 36.6 | 0.0 | 17.5 | 29.8 |
| Infants (<1 year) | 17 | 0 | 8 | 25 |
| % | 15.2 | 0.0 | 20.0 | 15.5 |
| Children (1-10 years) | 5 | 0 | 0 | 5 |
| % | 4.5 | 0.0 | 0.0 | 3.1 |
| Adolescents (11-19 ye | 4 | 2 | 1 | 7 |
| % | 3.6 | 22.2 | 2.5 | 4.4 |
| Adults (>=20 years) | 45 | 7 | 24 | 76 |
| % | 40.2 | 77.8 | 60.0 | 47.2 |
| **Gender** |  |  |  |  |
| female | 50 | 4 | 16 | **70** |
| % | 44.6 | 44.4 | 40.0 | **43.5** |
| male | 62 | 5 | 24 | **91** |
| % | 55.4 | 55.6 | 60.0 | **56.5** |
| **Race** |  |  |  |  |
| african | 110 | 9 | 40 | **159** |
| % | 98.2 | 100 | 100 | **98.8** |
| asian\_indian | 2 | 0 | 0 | **2** |
| % | 1.79 | 0 | 0 | **1.24** |
| **Hospital units** |  |  |  |  |
| Adult ICU | 20 | 9 | 9 | 38 |
| % | 17.9 | 100.0 | 22.5 | 23.6 |
| Burns Unit | 8 | 0 | 0 | 8 |
| % | 7.1 | 0.0 | 0.0 | 5.0 |
| NICU | 53 | 0 | 14 | 67 |
| % | 47.3 | 0.0 | 35.0 | 41.6 |
| Pediatric ICU | 3 | 0 | 0 | 3 |
| % | 2.7 | 0.0 | 0.0 | 1.9 |
| Renal Unit | 28 | 0 | 17 | 45 |
| % | 25.0 | 0.0 | 42.5 | 28.0 |
| Median number of adults in the household (IQR) | 2 (2, 3) | 4 (2, 6) | 3 (2, 4) | **2 (2, 3)** |
| Median number of children in the household (IQR) | 1 (1, 2) | 1 (0, 3) | 1 (0, 2) | **1 (0, 2)** |
| **Where received Healthcare with (overnight hospital stay) in the last 6 months** |  |  |  |  |
| Abroad | 1 | 0 | 0 | **1** |
| % | 0.9 | 0 | 0 | **0.6** |
| Kenya | 25 | 0 | 9 | **34** |
| % | 22.3 | 0 | 22.5 | **21.1** |
| No | 75 | 8 | 31 | **114** |
| % | 67.0 | 88.9 | 77.5 | **70.8** |
| Unknown | 11 | 1 | 0 | **12** |
| % | 9.8 | 11.1 | 0 | **7.5** |
| **Received healthcare in Kenya *(Most recent visit in the last 6 months)*** |  |  |  |  |
| member\_of\_household | 4 | - | 5 | **9** |
| % | 16.0 |  | 55.6 | **26.5** |
| patient | 21 | - | 4 | **25** |
| % | 84.0 |  | 44.4 | **73.5** |
| **Median number of days of Hospital stay (IQR) *(Most recent visit in the last 6 months)*** | 8 (3, 14) | - | 6 (6, 7) | **7 (5, 14)** |
| **Was this an ICU admission? *(Most recent visit in the last 6 months)*** |  |  |  |  |
| yes | 2 |  | 1 | 3 |
| **%** | 8.0 |  | 11.1 | 8.8 |
| no | 23 |  | 8 | 31 |
| **%** | 92.0 |  | 88.9 | 91.2 |
| **Received healthcare in Kenya *(*Second most *recent visit in the last 6 months)*** |  |  |  |  |
| member\_of\_household | 2 | - | 0 | 2 |
| % | 22.2 |  | 0 | 20.0 |
| patient | 7 | - | 1 | 8 |
| % | 77.8 |  | 100 | 80.0 |
| **Median number of days of Hospital stay (IQR) *(second most recent visit in the last 6 months)*** | 4 (1, 12) | - | 18 (18, 18) | **5.5 (1, 14)** |
| **Was this an ICU admission? *(second most recent visit in the last 6 months)*** |  |  |  |  |
| yes | 1 |  | 0 | 1 |
| **%** | 11.1 |  | 0 | 10.0 |
| no | 8 |  | 1 | 9 |
| **%** | 88.9 |  | 100 | 90.0 |
| **Received healthcare in Kenya *(Third* most *recent visit in the last 6 months)*** |  |  |  |  |
| patient | 1 |  | 1 | **2** |
| % | 100.0 |  | 100.0 | **100.0** |
| **Median number of days of Hospital stay (IQR) *(Third most recent visit in the last 6 months)*** | 1 (1, 1) | - | 2 (2, 2) | **1.5 (1, 2)** |
| **Was this an ICU admission? *(third most recent visit in the last 6 months)*** |  |  |  |  |
| no | 1 |  | 1 | **2** |
| % | 100.0 |  | 100.0 | **100.0** |
| **Received healthcare in Kenya *(Fourth* most *recent visit in the last 6 months)*** |  |  |  |  |
| patient | **-** | **-** | 1 | **1** |
| % |  |  | 100.0 | **100.0** |
| **Median number of days of Hospital stay (IQR) *(Fourth most recent visit in the last 6 months)*** | - | - | 3 (3, 3) | **3 (3, 3)** |
| **Was this an ICU admission? *(fourth most recent visit in the last 6 months)*** |  |  |  |  |
| no | - | - | 1 | **1** |
| % |  |  | 100.0 | **100.0** |
| **ANTIBIOTIC USE** | | | | |
| **Antibiotic use for the last 6 months** |  |  |  |  |
| yes | 18 | 1 | 8 | **27** |
| % | 16.1 | 11.1 | 20.0 | **16.8** |
| no | 73 | 4 | 25 | **102** |
| % | 65.2 | 44.4 | 62.5 | **63.4** |
| unknown | 21 | 4 | 7 | **32** |
| % | 18.8 | 44.4 | 17.5 | **19.9** |
| **Most recent antibiotic used** |  |  |  |  |
| Amoxicillin | 2 | 0 | 0 | **2** |
| % | 11.1 | 0 | 0 | **7.4** |
| Cetriaxone | 1 | 0 | 1 | **2** |
| % | 5.6 | 0 | 12.5 | **7.4** |
| Amoxicillin and enzyme inhibitor | 3 | 0 | 3 | **6** |
| % | 16.7 | 0 | 37.5 | **22.2** |
| Flucloxacillin | 1 | 0 | 1 | **2** |
| % | 5.6 | 0 | 12.5 | **7.4** |
| Gentamicin | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| Levofloxacin | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| Meropenem | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| Metronidazole (oral rectal) | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| Azithromycin | 1 | 0 | 1 | **2** |
| % | 5.6 | 0 | 12.5 | **7.4** |
| Sulfamethoxazole and trimethoprim | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| Benzathinebenzylpenicillin | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| Trimethoprim | 1 | 0 | 1 | **2** |
| % | 5.6 | 0 | 12.5 | **7.41** |
| Vancomycin (parenteral) | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| ciprofolaxin | 0 | 1 | 0 | **1** |
| % | 0 | 100 | 0 | **3.7** |
| augmentin | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| NA | 1 | 0 | 0 | **1** |
| % | 5.6 | 0 | 0 | **3.7** |
| unknown | 0 | 0 | 1 | **1** |
| % | 0 | 0 | 12.5 | **3.7** |
| **Route of administering the most recent antibiotic used** |  |  |  |  |
| intravenous | 6 | 0 | 2 | **8** |
| % | 33.3 | 0 | 25 | **29.6** |
| oral | 12 | 1 | 6 | **19** |
| % | 66.7 | 100 | 75 | **70.4** |
| **Median time in days on the antibiotic (most recent)** | 5 (3, 7) | 124 (124, 124) | 4.5 (3.5, 8) | **5 (3, 7)** |
| **Second most recent antibiotic used** |  |  |  |  |
| Amoxicillin and enzyme inhibitor | 1 | - | 0 | **1** |
| % | 12.5 |  | 0 | **11.1** |
| Benzylpenicillin | 1 | - | 0 | **1** |
| % | 12.5 |  | 0 | **11.1** |
| Ceftazidime | 2 | - | 0 | **2** |
| % | 25 |  | 0 | **22.2** |
| Clarithromycin | 1 | - | 0 | **1** |
| % | 12.5 |  | 0 | **11.1** |
| Gentamicin | 0 | - | 1 | **1** |
| % | 0 |  | 100.0 | **11.1** |
| Metronidazole (oral rectal) | 1 | - | 0 | **1** |
| % | 12.5 |  | 0 | **11.1** |
| Sulfamethoxazole | 1 | - | 0 | **1** |
| % | 12.5 |  | 0 | **11.1** |
| Vancomycin (parenteral) | 1 | - | 0 | **1** |
| % | 12.5 |  | 0 | **11.1** |
| **Route of administering second most antibiotic used** |  |  |  |  |
| intravenous | 5 | - | 1 | **6** |
| % | 62.5 |  | 100.0 | **66.7** |
| oral | 3 | - | 0 | **3** |
| % | 37.5 |  | 0 | **33.3** |
| **Median time in days on the antibiotic (second most recent)** | 4.5 (3, 9) | - | 2 (2, 2) | **4 (3, 8)** |
| **Third most recent antibiotic used** |  |  |  |  |
| Amoxicillin and enzyme inhibitor | 1 | - | - | 1 |
| % | 33.3 |  |  | 33.3 |
| Metronidazole (oral rectal) |  |  |  | 1 |
| % | 33.3 |  |  | 33.3 |
| Piperacillin and enzyme inhibitor |  |  |  | 1 |
| % | 33.3 |  |  | 33.3 |
| **Route of administering third most antibiotic used** |  |  |  |  |
| intravenous | 1 | - | - | 1 |
| % | 33.3 |  |  | 33.3 |
| oral | 2 | - | - | 2 |
| % | 66.7 |  |  | 66.7 |
| **Median time in days on the antibiotic (third most recent)** | 3 (2, 4) | - | - | **3 (2, 4)** |
| **Fourth most recent antibiotic used** |  |  |  |  |
| Amoxicillin and enzyme inhibitor | 1 | - | - | **1** |
| **%** | 100.0 |  |  | **100.0** |
| **Route of administering fourth most antibiotic used** |  |  |  |  |
| **Oral** | 1 | - | - | **1** |
| **%** | 100.0 |  |  | **100.0** |
| **Median time in days on the antibiotic (fourth most recent)** | 6 (6, 6) | - | - | 6 (6, 6) |
| **Antifungal Use** | | | | |
| **Antifungal use in the last 6 months** |  |  |  |  |
| yes | 2 | 0 | 2 | **4** |
| % | 1.8 | 0 | 5 | **2.5** |
| no | 86 | 5 | 34 | **125** |
| % | 76.8 | 55.56 | 85 | **77.6** |
| unknown | 24 | 4 | 4 | **32** |
| % | 21.4 | 44.4 | 10 | **19.9** |
| **Antifungal Indication** |  |  |  |  |
| prophylaxis | 1 |  | 0 | 1 |
| **%** | 50.0 |  | 0 | 25.0 |
| treatment | 1 |  | 2 | 3 |
| **%** | 50.0 |  | 100 | 75.0 |
| **Antifungal treatment** |  |  |  |  |
| candidemia | 0 |  | 2 | 2 |
| **%** | 0 |  | 100.0 | 66.7 |
| other | 1 |  | 0 | 1 |
| **%** | 100.0 |  | 0 | 33.3 |
| **Name of antifungal used** |  |  |  |  |
| Nystatin | 1 | - | 0 | **1** |
| % | 50.0 |  | 0 | **25.0** |
| Candid B | 0 | - | 1 | **1** |
| % | 0 |  | 50.0 | **25** |
| Clotrimazole | 1 | - | 0 | **1** |
| % | 50.0 |  | 0 | **25.0** |
| unknown | 0 | - | 1 | **1** |
| % | 0 |  | 50.0 | **25.0** |
| **Route of administering** |  |  |  |  |
| oral | 1 | - | 1 | **2** |
| % | 50.0 |  | 50.0 | **50.0** |
| topical | 1 | - | 1 | **2** |
| % | 50.0 |  | 50.0 | **50.0** |
| **Median time in days on Antifungal** | 3.5 (2, 5) | - | 61 (5, 117) | **5 (3.5, 61)** |
| **Surgeries Done** | | | | |
| **Surgeries before this admission** |  |  |  |  |
| yes | 7 | 2 | 3 | **12** |
| % | 6.3 | 22.2 | 7.5 | **7.5** |
| no | 99 | 7 | 36 | **142** |
| % | 88.4 | 77.8 | 90.0 | **88.2** |
| unknown | 6 | 0 | 1 | **7** |
| % | 5.4 | 0 | 2.5 | **4.4** |
| **Surgery Type** |  |  |  |  |
| AV fistula creation | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| Craniectomy | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| fixation of fracture | 0 | 0 | 1 | **1** |
| % | 0 | 0 | 33.3 | **8.3** |
| Fistula | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| Haemodialysis carth.. | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| Kidney Transplant | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| Kidney stone removal | 0 | 0 | 1 | **1** |
| % | 0 | 0 | 33.3 | **8.3** |
| Laparascopic cholesystectomy | 0 | 0 | 1 | **1** |
| % | 0 | 0 | 33.3 | **8.3** |
| nephrostomy tube insertion | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| spine decompression | 0 | 1 | 0 | **1** |
| % | 0 | 50.0 | 0 | **8.3** |
| T5-T10 posterior fusion | 0 | 1 | 0 | **1** |
| % | 0 | 50 | 0 | **8.3** |
| tunnel cuffed catheter | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| **Surgery location** |  |  |  |  |
| bedside | 1 | 0 | 0 | **1** |
| % | 14.3 | 0 | 0 | **8.3** |
| operating\_room | 6 | 2 | 3 | **11** |
| % | 85.7 | 100.0 | 100.0 | **91.7** |
| **Surgery facility** |  |  |  |  |
| Alliance Hospital | 1 | 0 | 0 | 1 |
| % | 14.3 | 0.0 | 0.0 | 8.3 |
| Coptic Hospital | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 33.3 | 8.3 |
| KNH | 6 | 1 | 0 | 7 |
| % | 85.7 | 50.0 | 0.0 | 58.3 |
| Mater Hospital | 0 | 1 | 0 | 1 |
| % | 0 | 50.0 | 0 | 8.3 |
| TNH | 0 | 0 | 2 | 2 |
| % | 0 | 0 | 66.7 | 16.7 |

Table 2\_Medical Record Abstraction Form (PPS)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **KNH (n=112)** | **NSIRH (n=9)** | **TNH (n=40)** | **Total (n=161)** |
| **Median time in days admitted in the hospital** | 5 (2, 16) | 70 (9, 172) | 1 (0, 16) | **5 (1, 20)** |
| **Median time in days admitted in the Unit** | 4 (2, 11.5) | 70 (9, 172) | 0.5 (0, 8) | **4 (1, 13)** |
| **Current Location** |  |  |  |  |
| Adult ICU | 20 | 9 | 8 | 37 |
| **%** | 17.9 | 100.0 | 20.0 | 23.0 |
| Burns Unit | 8 | 0 | 0 | 8 |
| **%** | 7.1 | 0.0 | 0.0 | 5.0 |
| NICU | 53 | 0 | 13 | 66 |
| **%** | 47.3 | 0.0 | 32.5 | 41.0 |
| Pediatric ICU | 6 | 0 | 2 | 8 |
| **%** | 5.4 | 0.0 | 5.0 | 5.0 |
| Renal Unit | 25 | 0 | 17 | 42 |
| **%** | 22.3 | 0.0 | 42.5 | 26.1 |
| **Room for the current location** *(See table 2a below)* |  |  |  |  |
| **Previous location** |  |  |  |  |
| Adult ICU | 19 | **-** | 2 | 21 |
| **%** | 82.6 |  | 20.0 | 63.6 |
| NICU | 1 | **-** | 7 | 8 |
| **%** | 4.4 |  | 70.0 | 24.2 |
| Pediatric ICU | 3 | **-** | 1 | 4 |
| **%** | 13.0 |  | 10.0 | 12.1 |
| **Reason for current admission** |  |  |  |  |
| Sepsis | 45 (40.2%) | 0 | 23 (57.5%) | **68 (42.2%)** |
| Cardiovascular | 8 (7.1%) | 0 | 3 (7.5%) | **11 (6.8%)** |
| Respiratory | 33 (29.5%) | 0 | 7 (17.5%) | **40 (24.8%)** |
| Central Nervous System (CNS) | 19 (17.0%) | 0 | 2 (5.0%) | **21 (13.0%)** |
| Renal | 26 (23.2%) | 0 | 16 (40.0%) | **42 (26.1%)** |
| Orthopedic | 0 | 9 (100%) | 1 (2.5%) | **10 (6.2%)** |
| Gastrointestinal | 2 (1.8%) | 0 | 0 | **2 (1.2%)** |
| Surgical | 3 (2.7%) | 0 | 1 (2.5%) | **4 (2.5%)** |
| Drug Ingestion and overdose | 1 (0.9%) | 0 | 0 | **1 (0.6%)** |
| Endocrine | 2 (1.8%) | 0 | 1 (2.5%) | **3 (1.9%)** |
| Miscellaneous | 29 (25.9%) | 0 | 6 (15.0%) | **35 (21.7%)** |
|  |  |  |  |  |
| **Median Apache Score (IQR) …..***n=13*  *Those in critical care, ≥ 18years* | 13 (11, 21) | - | 21 (8, 24) | **13 (11, 21)** |
| **Median Pelod Score (IQR) …..***n=20*  *Those in critical care, < 18 years* | 2.3 (0, 7.5) | - | 2.3 (0, 4.9) | **2.3 (0, 7.5)** |
| **Median mortality rate (IQR) …..***n=20*  *Those in critical care, < 18 years* | 0.4 (0.3, 7.1) | - | 0.4 (0.4, 1.2) | **0.4 (0.4, 7.1)** |
| **Had an MDRO in the 90 days before the primary surveillance culture was collected** |  |  |  |  |
| yes | 5 | 0 | 0 | 5 |
| % | 4.5 | 0 | 0 | 3.1 |
| no | 107 | 9 | 40 | 156 |
| % | 95.5 | 100.0 | 100.0 | 96.9 |
| **Type of MDRO** |  |  |  |  |
| MRSA | 1 | - | - | **1** |
| % | 0.2 |  |  | **0.2** |
| Klb | 2 | - | - | **2** |
| % | 0.4 |  |  | **0.4** |
| Other, acinetobacter bauneria | 1 | - | - | **1** |
| % | 0.2 |  |  | **0.2** |
| Other, E.coli | 1 | - | - | **1** |
| % | 0.2 |  |  | **0.2** |
| **Did the patient have any of the following during this admission*?*** |  |  |  |  |
| Central venous catheter (e.g. IVCs, SVC lines, femoral lines, PICCs) | 21 (18.8%) | 0 | 8 (20.0%) | **29 (18.0%)** |
| Peripheral venous catheter | 66 (58.9%) | 7 (77.8%) | 18 (45.0%) | **91 (56.5%)** |
| Other non-peripheral access (e.g. midlines) | 6 (5.4%) | 0 | 0 | **6 (3.7%)** |
| Urinary catheter | 24 (21.4%) | 8 (88.9%) | 5 (12.5%) | **37 (23.0%)** |
| Nephrostomy tube | 1 (0.9%) | 0 | 0 | **1 (0.6%)** |
| Surgical –ostomy without tube | 0 | 1 (11.1%) | 0 | **1 (0.6%)** |
| Surgical drain | 4 (3.6%) | 0 | 0 | **4 (2.5%)** |
| Other -ostomy tube | 4 (3.6%) | 0 | 0 | **4 (2.5%)** |
| **Other -ostomy tube, specify** |  |  |  |  |
| *Gastrotomy And Jejunostomy* | *1 (33.3%)* | ***-*** | ***-*** | ***1 (33.3%)*** |
| *Gastrotomy Tube* | *1 (33.3%)* | ***-*** | ***-*** | ***1 (33.3%)*** |
| *Jejunostomy And Gastrotomy* | *1 (33.3%)* | ***-*** | ***-*** | ***1 (33.3%)*** |
|  |  |  |  |  |
| Dialysis | 22 (19.6%) | 0 | 19 (47.5%) | 41 (25.5%) |
| Radiology | 23 (20.5%) | 5 (55.6%) | 13 (32.5%) | 41 (25.5%) |
| Receiving enteral feeding | 4 (3.6%) | 0 | 1 (2.5%) | 5 (3.1%) |
| Endotracheal tube | 16 (14.3%) | 0 | 3 (7.5%) | 19 (11.8%) |
| Tracheostomy | 2 (1.8%) | 0 | 1 (2.5%) | 3 (1.9%) |
| Mechanical ventilation | 19 (17.0%) | 0 | 2 (5.0%) | 21 (13.0%) |
| Gastrointestinal tube (PEG/PEJ) | 9 (8.0%) | 0 | 1 (2.5%) | 10 (6.2%) |
| Nasogastric/nasoduodenal Tube | 34 (30.4%) | 2 (22.2%) | 10 (25.0%) | 46 (28.6%) |
| PEG tube changes | 1 (0.9%) | 0 | 0 | **1 (0.6%)** |
|  |  |  |  |  |
| **Received some form of bath while in the ICU** |  |  |  |  |
| yes | 55 | 9 | 15 | 79 |
| **%** | 49.1 | 100 | 37.5 | 49.1 |
| no | 10 | 0 | 11 | 21 |
| **%** | 8.9 | 0 | 27.5 | 13.0 |
| unknown | 27 | 0 | 4 | 31 |
| **%** | 24.1 | 0 | 10 | 19.3 |
| na | 20 | 0 | 10 | 30 |
| **%** | 17.9 | 0 | 25 | 18.6 |
| **Type of Bath** |  |  |  |  |
| Basin\_bath | 24 | 9 | 2 | 35 |
| **%** | 43.6 | 100.0 | 13.3 | 44.3 |
| CHG | 7 | 0 | 10 | 17 |
| **%** | 12.7 | 0.0 | 66.7 | 21.5 |
| Showered | 1 | 0 | 0 | 1 |
| **%** | 1.8 | 0.0 | 0.0 | 1.3 |
| Wipes\_non-chg | 23 | 0 | 3 | 26 |
| **%** | 41.8 | 0.0 | 20.0 | 32.9 |
| **Surgeries** | | | | |
| **Surgeries during this admission** |  |  |  |  |
| yes | 25 | 7 | 4 | 36 |
| % | 22.3 | 77.8 | 10.0 | 22.4 |
| no | 87 | 2 | 36 | 125 |
| % | 77.7 | 22.2 | 90.0 | 77.6 |
| **Surgery Name** *(see table 2b below)* |  |  |  |  |
| **Location where surgery was done** |  |  |  |  |
| Bedside | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 25.0 | 2.8 |
| Interventional\_Radiology | 0 | 0.0 | 1 | 1.0 |
| % | 0 | 0 | 25.0 | 2.8 |
| Operating\_Room | 24 | 7 | 2 | 33 |
| % | 96.0 | 100.0 | 50.0 | 91.7 |
| Procedure Room | 1 | 0 | 0 | 1.0 |
| % | 4.0 | 0 | 0 | 2.8 |
| **Facility where surgery was done** |  |  |  |  |
| KNH | 25 | 0 | 0 | 25 |
| % | 100.0 | 0 | 0 | 69.4 |
| NSIRH | 0 | 7 | 0 | 7 |
| % | 0 | 100.0 | 0 | 19.4 |
| TNH | 0 | 0 | 4 | 4 |
| % | 0 | 0 | 100 | 11.1 |
| **Surgery name (second most recent)** |  |  |  |  |
| Bilateral Nephrostomy tube insertion | 1 | - | - | 1 |
| % | 33.3 |  |  | 33.3 |
| Craniotomy excision of tumour | 1 | - | - | 1 |
| % | 33.3 |  |  | 33.3 |
| Explorative Laparotomy And Repair Of Anastomotic Leak | 1 | - | - | 1 |
| % | 33.3 |  |  | 33.3 |
| **Location where surgery was done (second most recent)** |  |  |  |  |
| operating\_room | 3 | - | - | 3 |
| % | 100.0 |  |  | 100.0 |
| **Facility where surgery was done (second most recent)** |  |  |  |  |
| KNH | 3 | - | - | 3 |
| % | 100.0 |  |  | 100.0 |
| **Surgery name (Third most recent)** |  |  |  |  |
| Bilateral ar Holes with an EVD Drain | 1 | - | - | 1 |
| % | 50.0 |  |  | 50.0 |
| Total Gastrectomy | 1 | - | - | 1 |
| % | 50.0 |  |  | 50.0 |
| **Location where surgery was done (third most recent)** |  |  |  |  |
| operating\_room | 2 | - | - | 2 |
| % | 100.0 |  |  | 100.0 |
| **Facility where surgery was done (second most recent)** |  |  |  |  |
| KNH | 2 | - | - | 2 |
| % | 100.0 |  |  | 100.0 |
| **Anti fungals** | | | | |
| **Antifungal drugs received during this admission** |  |  |  |  |
| yes | 4 | 0 | 2 | 6 |
| % | 3.6 | 0 | 5.0 | 3.7 |
| no | 107 | 9 | 38 | 154 |
| % | 95.5 | 100.0 | 95.0 | 95.7 |
| unknown | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| **Antifungal indication** |  |  |  |  |
| Sepsis | 1 | **-** | 0 | 1 |
| **%** | 25.0 |  | 0 | 16.7 |
| empiric | 1 | **-** | 0 | 1 |
| **%** | 25.0 |  | 0 | 16.7 |
| treatment | 1 | **-** | 0 | 1 |
| **%** | 25.0 |  | 0 | 16.7 |
| Not documented | 1 | **-** | 2 | 3 |
| **%** | 25.0 |  | 100.0 | 50.0 |
| **Antifungal drug name** |  |  |  |  |
| Nystatin | 1 | - | 0 | 1 |
| % | 25.0 |  | 0 | 16.7 |
| Fluconazole | 3 | - | 1 | 4 |
| % | 75.0 |  | 50.0 | 66.7 |
| Posaconazole | 0 | - | 1 | 1 |
| % | 0 |  | 50.0 | 16.7 |
| **Route of administering antifungal** |  |  |  |  |
| intravenous | 2 | - | 1 | 3 |
| % | 50.0 |  | 50.0 | 50.0 |
| oral | 2 | - | 1 | 3 |
| % | 50.0 |  | 50.0 | 50.0 |
| **Median time in days on antifungal** | 7 (5.5, 8) | - | 6.5 (6, 7) | **7 (6, 7)** |
| **Antibacterial** | | | | |
| **Antibacterial drugs received during this admission** |  |  |  |  |
| yes | 76 | 8 | 19 | 103 |
| % | 67.9 | 88.9 | 47.5 | 64.0 |
| no | 36 | 1 | 21 | 58 |
| % | 32.1 | 11.1 | 52.5 | 36.0 |
| **Antibacterial Indication** |  |  |  |  |
| Empiric | 1 | 0 | 1 | 2 |
| **%** | 1.3 | 0 | 5.3 | 1.9 |
| Meningitis | 1 | 0 | 0 | 1 |
| **%** | 1.3 | 0 | 0 | 1.0 |
| Not documented | 22 | 6 | 1 | 29 |
| **%** | 29.0 | 75.0 | 5.3 | 28.2 |
| Pneumonia | 2 | 0 | 0 | 2 |
| **%** | 2.6 | 0 | 0 | 1.9 |
| Prophylaxis | 26 | 2 | 6 | 34 |
| **%** | 34.2 | 25.0 | 31.6 | 33.0 |
| Sepsis | 8 | 0 | 8 | 16 |
| **%** | 10.5 | 0 | 42.1 | 15.5 |
| Treatment | 16 | 0 | 3 | 19 |
| **%** | 21.1 | 0 | 15.8 | 18.5 |
| **Antibacterial Name** *(see the table 2c below)* |  |  |  |  |
| **Antibacterial Route of administration** |  |  |  |  |
| intravenous | 72 | 5 | 16 | 93 |
| **%** | 94.7 | 62.5 | 84.2 | 90.3 |
| oral | 3 | 3 | 2 | 8 |
| **%** | 4.0 | 37.5 | 10.5 | 7.8 |
| topical | 1 | 0 | 1 | 2 |
| **%** | 1.3 | 0 | 5.3 | 1.9 |
| **Median time in days on antibacterial** | 4.5 (2, 6) | 4.5 (3, 5.5) | 3 (2, 5) | **4 (2, 6)** |
| **Antibacterial Indication\_ second most recent** |  |  |  |  |
| Prophylaxis | 20 | 0 | 2 | 22 |
| **%** | 30.3 | 0 | 15.4 | 25.6 |
| Treatment | 13 | 0 | 1 | 14 |
| **%** | 19.7 | 0 | 7.7 | 16.3 |
| Sepsis | 7 | 0 | 6 | 13 |
| **%** | 10.6 | 0 | 46.2 | 15.1 |
| Empiric | 2 | 0 | 1 | 3 |
| **%** | 3.0 | 0 | 7.7 | 3.5 |
| Pneumonia | 1 | 0 | 1 | 2 |
| **%** | 1.5 | 0 | 7.7 | 2.3 |
| Conjunctivitis | 0 | 0 | 1 | 1 |
| **%** | 0 | 0 | 7.7 | 1.2 |
| vancomycin | 1 | 0 | 0 | 1 |
| **%** | 1.5 | 0 | 0 | 1.2 |
| Not documented | 22 | 7 | 1 | 30 |
| **%** | 33.3 | 100.0 | 7.7 | 34.9 |
| **Antibacterial Name\_ second most recent** *(see the table 2d below)* |  |  |  |  |
| **Antibacterial route of administration\_ second most recent** |  |  |  |  |
| intravenous | 60 | 4 | 11 | 75 |
| **%** | 90.9 | 57.1 | 84.6 | 87.2 |
| oral | 3 | 3 | 1 | 7 |
| **%** | 4.6 | 42.9 | 7.7 | 8.1 |
| topical | 3 | 0 | 1 | 4 |
| **%** | 4.6 | 0.0 | 7.7 | 4.7 |
| **Median time in days on antibacterial\_ second most recent** | 4.5 (3, 6) | 2 (1, 5) | 4 (2, 7) | **4 (2, 6)** |
| **Antibacterial Indication\_ Third most recent** |  |  |  |  |
| Treatment | 7 | 0 | 1 | 8 |
| % | 25.0 | 0.0 | 16.7 | 20.5 |
| Prophylaxis | 5 | 0 | 1 | 6 |
| % | 17.9 | 0.0 | 16.7 | 15.4 |
| Sepsis | 3 | 0 | 1 | 4 |
| % | 10.7 | 0.0 | 16.7 | 10.3 |
| Empiric | 2 | 0 | 1 | 3 |
| **%** | 7.1 | 0.0 | 16.7 | 7.7 |
| Tuberculosis | 0 | 1 | 0 | 1 |
| **%** | 0 | 20 | 0 | 2.6 |
| pneumonia | 0 | 0 | 1 | 1 |
| **%** | 0 | 0 | 16.7 | 2.6 |
| Not documented | 11 | 4 | 1 | 16 |
| **%** | 39.3 | 80.0 | 16.7 | 41.0 |
| **Antibacterial Name\_ third most recent** *(see the table 2e below)* |  |  |  |  |
| **Antibacterial route of administration\_ third most recent** |  |  |  |  |
| intravenous | 23 | 1 | 6 | 30 |
| **%** | 82.1 | 20.0 | 100.0 | 76.9 |
| oral | 2 | 4 | 0 | 6 |
| **%** | 7.1 | 80.0 | 0 | 15.4 |
| topical | 3 | 0 | 0 | 3 |
| **%** | 10.7 | 0 | 0 | 7.7 |
| **Median time in days on antibacterial\_ third most recent** | 4.5 (2, 6) | 4 (1, 5) | 4 (4, 5) | **4 (2, 6)** |
| **Antibacterial Indication\_ Fourth most recent** |  |  |  |  |
| Prophylaxis | 4 | 0 | 2 | 6 |
| **%** | 21.1 | 0 | 40.0 | 21.4 |
| Treatment | 4 | 0 | 0 | 4 |
| **%** | 21.1 | 0 | 0 | 14.3 |
| Sepsis | 2 | 0 | 0 | 2 |
| **%** | 10.5 | 0 | 0 | 7.1 |
| Eye Drops For Eye Infection | 1 | 0 | 0 | 1 |
| **%** | 5.3 | 0 | 0 | 3.6 |
| Empiric | 0 | 0 | 1 | 1 |
| **%** | 0 | 0 | 20.0 | 3.6 |
| Pneumonia | 0 | 0 | 1 | 1 |
| **%** | 0 | 0 | 20.0 | 3.6 |
| Not documented | 8 | 4 | 1 | 13 |
| **%** | 42.1 | 100.0 | 20.0 | 46.4 |
| **Antibacterial Name\_ Fourth most recent** *(see the table 2f below)* |  |  |  |  |
| **Antibacterial route of administration\_ Fourth most recent** |  |  |  |  |
| intravenous | 16 | 2 | 4 | 22 |
| **%** | 84.2 | 50.0 | 80.0 | 78.6 |
| oral | 1 | 2 | 1 | 4 |
| **%** | 5.3 | 50.0 | 20.0 | 14.3 |
| topical | 2 | 0 | 0 | 2 |
| **%** | 10.5 | 0 | 0 | 7.1 |
| **Median time in days on antibacterial\_ Fourth most recent** | 3.5 (3, 6) | 4 (3, 6) | 4 (4, 4) | **4 (3, 6)** |
| **Antibacterial Indication\_ Fifth most recent** |  |  |  |  |
| Treatment | 3 | 0 | 1 | 4 |
| **%** | 42.9 | 0 | 100.0 | 40.0 |
| Sepsis | 1 | 0 | 0 | 1 |
| **%** | 14.3 | 0 | 0 | 10.0 |
| Not documented | 3 | 2 | 0 | 5 |
| **%** | 42.9 | 100.0 | 0 | 50.0 |
| **Antibacterial Name\_ Fifth most recent** *(see the table 2g below)* |  |  |  |  |
| **Antibacterial route of administration\_ Fifth most recent** |  |  |  |  |
| intravenous | 6 | 1 | 1 | 8 |
| **%** | 85.7 | 50.0 | 100.0 | 80.0 |
| oral | 1 | 1 | 0 | 2 |
| **%** | 14.3 | 50 | 0 | 20.0 |
| **Median time in days on antibacterial\_ Fifth most recent** | 5 (4, 8) | 4 (4, 4) | 1 (1, 1) | **4.5 (4, 6)** |
| **Antibacterial Indication\_ Sixth most recent** |  |  |  |  |
| Treatment | 2 | 0 | 1 | 3 |
| **%** | 50.0 | 0.0 | 100.0 | 42.9 |
| Sepsis | 1 | 0 | 0 | 1 |
| **%** | 25.0 | 0.0 | 0.0 | 14.3 |
| Not documented | 1 | 2 | 0 | 3 |
| **%** | 25.0 | 100.0 | 0.0 | 42.9 |
| **Antibacterial Name\_ Sixth most recent** |  |  |  |  |
| Meropenem | 1 | 1 | 1 | 3 |
| % | 25.0 | 50.0 | 100.0 | 42.9 |
| Mupirocin | 1 | 0 | 0 | 1 |
| % | 25.0 | 0.0 | 0.0 | 14.3 |
| Nitrofurantoin | 0 | 1 | 0 | 1 |
| % | 0.0 | 50.0 | 0.0 | 14.3 |
| Tetracycline | 1 | 0 | 0 | 1 |
| % | 25.0 | 0.0 | 0.0 | 14.3 |
| **Antibacterial route of administration\_ Sixth most recent** |  |  |  |  |
| intravenous | 3 | 1 | 1 | 5 |
| **%** | 75.0 | 50.0 | 100.0 | 71.4 |
| oral | 0 | 1 | 0 | 1 |
| **%** | 0.0 | 50.0 | 0.0 | 14.3 |
| topical | 1 | 0 | 0 | 1 |
| **%** | 25.0 | 0.0 | 0.0 | 14.3 |
| **Median time in days on antibacterial\_ Sixth most recent** | 5.5 (2.5, 7.5) | 7 (6, 8) | 3 (3, 3) | **6 (3, 8)** |
| **Other treatments received during this admission** |  |  |  |  |
| Cytotoxic chemotherapy |  |  |  |  |
| no | 112 | 9 | 39 | 160 |
| **%** | 100.0 | 100.0 | 97.5 | 99.4 |
| unknown | 0 | 0 | 1 | 1 |
| **%** | 0.0 | 0.0 | 2.5 | 0.6 |
| Corticosteroids |  |  |  |  |
| yes | 13 | 2 | 6 | 21 |
| **%** | 11.6 | 22.2 | 15.0 | 13.0 |
| no | 96 | 7 | 34 | 137 |
| **%** | 85.7 | 77.8 | 85.0 | 85.1 |
| unknown | 3 | 0 | 0 | 3 |
| **%** | 2.7 | 0.0 | 0.0 | 1.9 |
| **Type and Dosage of Corticosteroids (***See table 2h below***)** |  |  |  |  |
| **Underlying conditions at time of admission** |  |  |  |  |
| yes | 43 | 2 | 27 | 72 |
| % | 38.4 | 22.2 | 67.5 | 44.7 |
| none | 66 | 7 | 13 | 86 |
| % | 58.9 | 77.8 | 32.5 | 53.4 |
| unknown | 3 | 0 | 0 | 3 |
| % | 2.7 | 0 | 0 | 1.9 |
| **Conditions:** |  |  |  |  |
| Chronic Lung Disease | 3 (2.7%) | 0 | 1 (2.5%) | 4 (2.5%) |
| Chronic Metabolic Disease | 9 (8.0%) | 0 | 14 (35.0%) | 23 (14.3%) |
| Cardiovascular Disease | 6 (5.4%) | 0 | 0 | 6 (3.7%) |
| Gastrointestinal Disease | 1 (0.9%) | 0 | 0 | 1 (0.6%) |
| Immunocompromised  Condition | 6 (5.4%) | 1 (11.1%) | 1 (2.5%) | 8 (5.0%) |
| Liver Disease | 0 | 0 | 1 (2.5%) | 1 (0.6%) |
| Malignancy | 5 (4.5%) | 0 | 0 | 5 (3.1%) |
| Neurologic Condition | 12 (10.7%) | 1 (11.1%) | 2 (5.0%) | 15 (9.3%) |
| Plegias/Paralysis | 1 (0.9%) | 1 (11.1%) | 0 | 2 (1.2%) |
| Renal Disease | 10 (8.9%) | 0 | 12 (30.0%) | 22 (13.7%) |
| *Median Highest serum creatinine in mcmol/L* | *822 (549, 1374)* | *-* | *910.5 ( 698.5, 1048.5)* | *898 (649, 1139)* |
| Skin Condition | 1 (0.9%) | 0 | 1 (2.5%) | 2 (1.2%) |
| Trauma | 2 (1.8%) | 1 (11.1%) | 0 | 3 (1.9%) |
| **Candida positive cultures during this admission** |  |  |  |  |
| *None was positive* |  |  |  |  |
| **Lab results on Candida swabs** |  |  |  |  |
| *Pending* |  |  |  |  |

**Table 2a\_ Current Location Room**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Room** | **KNH**  **n=112** | **NSIRH**  **n=9** | **TNH**  **n=40** | **Total**  **n=161** |
| 1 | 0 | 0 | 1 | 1 |
| % | 0.0 | 0.0 | 2.5 | 0.6 |
| 10 | 0 | 0 | 2 | 2 |
| % | 0 | 0 | 5.0 | 1.2 |
| 11 | 0 | 0 | 3 | 3 |
| % | 0 | 0 | 7.5 | 1.9 |
| 11b | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| 12 | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| 13 | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| 14 | 0 | 0 | 2 | 2 |
| % | 0 | 0 | 5.0 | 1.2 |
| 15 | 0 | 0 | 2 | 2 |
| % | 0 | 0 | 5.0 | 1.2 |
| 16 | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| 17 | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| 2 | 2 | 0 | 3 | 5 |
| % | 1.8 | 0 | 7.5 | 3.1 |
| 3 | 2 | 0 | 4 | 6 |
| % | 1.8 | 0 | 10.0 | 3.7 |
| 4 | 1 | 0 | 4 | 5 |
| % | 0.9 | 0 | 10.0 | 3.1 |
| 5 | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| 6 | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| 7 | 1 | 0 | 1 | 2 |
| % | 0.9 | 0 | 2.5 | 1.2 |
| 8 | 2 | 0 | 2 | 4 |
| % | 1.8 | 0 | 5 | 2.5 |
| 9 | 1 | 0 | 3 | 4 |
| % | 0.9 | 0 | 7.5 | 2.5 |
| B1 | 5 | 0 | 0 | 5 |
| % | 4.5 | 0 | 0 | 3.1 |
| B2 | 5 | 0 | 0 | 5 |
|  | 4.5 | 0 | 0 | 3.1 |
| B3 | 8 | 0 | 0 | 8 |
| % | 7.1 | 0 | 0 | 5.0 |
| CCU | 11 | 0 | 0 | 11 |
| % | 9.8 | 0 | 0 | 6.8 |
| ICU | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| Isolation | 3 | 0 | 0 | 3 |
| % | 2.7 | 0 | 0 | 1.9 |
| N/A | 5 | 7 | 6 | 18 |
| % | 4.5 | 77.8 | 15 | 11.2 |
| NICU 1 | 2 | 0 | 0 | 2 |
| % | 1.8 | 0 | 0 | 1.2 |
| NICU 2 | 3 | 0 | 0 | 3 |
| % | 2.7 | 0 | 0 | 1.9 |
| Nursery B2 | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| Nursery B3 | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| Neonatal ICU 2 | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| Nursery D | 25 | 0 | 0 | 25 |
| % | 22.3 | 0 | 0 | 15.5 |
| OPD | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| Paediatric Renal Unit | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| PICU | 2 | 0 | 0 | 2 |
| % | 1.8 | 0 | 0 | 1.2 |
| Renal unit | 2 | 0 | 0 | 2 |
| % | 1.8 | 0 | 0 | 1.2 |
| Side A | 14 | 0 | 0 | 14 |
| % | 12.5 | 0 | 0 | 8.7 |
| Side B | 8 | 0 | 0 | 8 |
| % | 7.1 | 0 | 0 | 5.0 |
| Step Down Ward | 1 | 0 | 0 | 1 |
| % | 0.9 | 0 | 0 | 0.6 |
| Transplant Room | 2 | 0 | 0 | 2 |
| % | 1.8 | 0 | 0 | 1.2 |
| unknown | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 2.5 | 0.6 |
| Not documented | 0 | 2 | 0 | 2 |
| % | 0 | 22.2 | 0 | 1.2 |

**Table 2b\_ Name of surgery\_ Medical abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Surgery Name** | **KNH** | **NSIRH** | **TNH** | **Total** |
| Abdominal Washout And Repair Of Anastomotic Leak | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Acdf | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Bilateral Thoracentesis | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 25 | 2.8 |
| Craniotomy,Duraplasty | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Decompressive Craniectomy, Evacuation And Debridement | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Emergency Exploratory Laperotomy And Right Hemizolectomy And Stoma Positioning | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Excision Of Scalp Mass | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| External Ventricular Drains | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Emergency Caeserian Section And Subtotal Hysterectomy | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Gastrostomy Tube Insertion | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Haemodialysis Catheter Insertion | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Jejunostomy Tube Insertion | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Lumbar 3,4 Decompression | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Peritoneal Dialysis Catheter Insertion | 2 | 0 | 0 | 2 |
| % | 8.0 | 0 | 0 | 5.6 |
| Peritoneal Dialysis | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Peritoneal Dialysis Catheter Insertion | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Repair Of Facial/Nasal/Orbital Fractures | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 25.0 | 2.8 |
| Right Open Heterotopic Kidney Allograft Transplant | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Rotational Flap | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Spine Decompression Stabilization And Biopsy | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Spine Stabilization | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Svc Venogram | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 25 | 2.8 |
| Surgical Debridment | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Surgical Debridment | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 2.8 |
| Temporal Dialysis Catheter Insertion | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Vp Shunt | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Vps Insertion | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| VPS Insertion And MMC Repair | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Ventriculoperitoneal Shunting | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Craniotomy | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Flexible Nasopharyngoscopy,Choanal Dilatation | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 25.0 | 2.8 |
| Insertion Of Temporary Hemodialysis Catheter | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Laparoscopic Excision | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Ventriculoperitoneal Shunt | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |
| Ventriuloperitoneal Shunt Insertion Plus Yelomeningoceal Repair | 1 | 0 | 0 | 1 |
| % | 4.0 | 0 | 0 | 2.8 |

**Table 2 c\_ Antibiotic Name\_ Medical Abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibacterial Name** | **KNH**  **n=76** | **NSIRH**  **n=8** | **TNH**  **n=19** | **Total**  **N=103** |
| Benzylpenicillin | 19 | 0 | 2 | 21 |
| % | 25.0 | 0 | 10.5 | 20.4 |
| Ceftriaxone | 13 | 3 | 1 | 17 |
| % | 17.1 | 37.5 | 5.3 | 16.5 |
| Amikacin | 7 | 0 | 1 | 8 |
| % | 9.2 | 0 | 5.3 | 7.8 |
| Benzathinebenzylpenicillin | 8 | 0 | 0 | 8 |
| % | 10.5 | 0 | 0 | 7.8 |
| Ceftazidime | 6 | 0 | 1 | 7 |
| % | 7.9 | 0 | 5.3 | 6.8 |
| Gentamicin | 3 | 1 | 2 | 6 |
| % | 4.0 | 12.5 | 10.5 | 5.8 |
| Amoxicillin and enzyme inhibitor | 2 | 2 | 1 | 5 |
| % | 2.6 | 25.0 | 5.3 | 4.9 |
| Cefuroxime | 2 | 0 | 2 | 4 |
| % | 2.6 | 0 | 10.5 | 3.9 |
| Ciprofloxacin | 0 | 2 | 1 | 3 |
| % | 0 | 25.0 | 5.3 | 2.9 |
| Flucloxacillin | 3 | 0 | 0 | 3 |
| % | 4.0 | 0 | 0 | 2.9 |
| Piperacillin and enzyme inhibitor | 2 | 0 | 1 | 3 |
| % | 2.6 | 0 | 5.3 | 2.9 |
| Levofloxacin | 1 | 0 | 1 | 2 |
| % | 1.3 | 0 | 5.3 | 1.9 |
| Trimethoprim | 0 | 0 | 2 | 2 |
| % | 0 | 0 | 10.5 | 1.9 |
| Cefotaxime | 0 | 0 | 2 | 2 |
| % | 0 | 0 | 10.5 | 1.9 |
| Augmentin | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Azithromycin | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Benzathine penicillin 9 | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Cefazolin | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Cefodizime | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Meropenem | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Metronidazole (parenteral) | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Sulfadiazine | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Sulfamethoxazole and trimethoprim | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Tazobactam | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 5.3 | 1.0 |
| Vancomycin (parenteral) | 1 | 0 | 0 | 1 |
| % | 1.3 | 0 | 0 | 1.0 |
| Other | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 5.3 | 1.0 |

**Table 2d\_ Antibiotic Name\_ Second most recent\_ Medical Abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibiotics** | **KNH**  **n=66** | **NSIRH**  **n=7** | **TNH**  **n=13** | **Total**  **n=86** |
| Amikacin | 6 | 0 | 4 | 10 |
| % | 9.1 | 0 | 30.8 | 11.6 |
| Azithromycin | 1 | 0 | 0 | 1 |
| % | 1.5 | 0 | 0 | 1.2 |
| Benzathinebenzylpenicillin | 3 | 0 | 0 | 3 |
| % | 4.6 | 0 | 0 | 3.5 |
| Benzylpenicillin | 2 | 0 | 0 | 2 |
| % | 3.0 | 0 | 0 | 2.3 |
| Cefazolin | 1 | 0 | 0 | 1 |
| % | 1.5 | 0 | 0 | 1.2 |
| Cefotaxime | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 7.7 | 1.2 |
| Ceftazidime | 5 | 0 | 0 | 5 |
| % | 7.6 | 0 | 0 | 5.8 |
| Ceftriaxone | 4 | 1 | 1 | 6 |
| % | 6.1 | 14.3 | 7.7 | 7.0 |
| Clarithromycin | 1 | 1 | 0 | 2 |
| % | 1.5 | 14.3 | 0 | 2.3 |
| Clindamycin | 0 | 1 | 0 | 1 |
| % | 0 | 14.3 | 0 | 1.2 |
| Flucloxacillin | 5 | 0 | 1 | 6 |
| % | 7.6 | 0 | 7.7 | 7.0 |
| Gentamicin | 22 | 3 | 2 | 27 |
| % | 33.3 | 42.9 | 15.4 | 31.4 |
| Levofloxacin | 1 | 1 | 0 | 2 |
| % | 1.5 | 14.3 | 0 | 2.3 |
| Meropenem | 7 | 0 | 1 | 8 |
| % | 10.6 | 0 | 7.7 | 9.3 |
| Metronidazole (oral rectal) | 1 | 0 | 1 | 2 |
| % | 1.5 | 0 | 7.7 | 2.3 |
| Metronidazole (parenteral) | 3 | 0 | 0 | 3 |
| % | 4.6 | 0 | 0 | 3.5 |
| Piperacillin and enzyme inhibitor | 1 | 0 | 1 | 2 |
| % | 1.5 | 0 | 7.7 | 2.3 |
| Polymyxin B | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 7.7 | 1.2 |
| Sulfadiazine | 2 | 0 | 0 | 2 |
| % | 3.0 | 0 | 0 | 2.3 |
| not indicated | 1 | 0 | 0 | 1 |
| % | 1.5 | 0 | 0 | 1.2 |

**Table 2e\_ Antibiotic Name\_ Third most recent\_ Medical Abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibiotic** | **KNH**  **n=28** | **NSIRH**  **n=5** | **TNH**  **n=6** | **Total**  **n=39** |
| Flucloxacillin | 5 | 0 | 0 | 5 |
| % | 17.9 | 0.0 | 0.0 | 12.8 |
| Amikacin | 4 | 0 | 0 | 4 |
| % | 14.3 | 0.0 | 0.0 | 10.3 |
| Ceftriaxone | 3 | 1 | 0 | 4 |
| % | 10.7 | 20.0 | 0.0 | 10.3 |
| Metronidazole (parenteral) | 2 | 0 | 1 | 3 |
| % | 7.1 | 0.0 | 16.7 | 7.7 |
| Benzylpenicillin | 1 | 0 | 1 | 2 |
| % | 3.6 | 0.0 | 16.7 | 5.1 |
| Ceftazidime | 2 | 0 | 0 | 2 |
| % | 7.1 | 0.0 | 0.0 | 5.1 |
| Meropenem | 2 | 0 | 0 | 2 |
| % | 7.1 | 0.0 | 0.0 | 5.1 |
| Gentamicin | 2 | 0 | 1 | 3 |
| % | 7.1 | 0.0 | 16.7 | 7.7 |
| Tetracycline | 2 | 0 | 0 | 2 |
| % | 7.1 | 0.0 | 0.0 | 5.1 |
| Anti TB'S | 0 | 1 | 0 | 1 |
| % | 0 | 20.0 | 0 | 2.6 |
| Amoxicillin | 0 | 1 | 0 | 1 |
| % | 0 | 20.0 | 0 | 2.6 |
| Amoxicillin and enzyme inhibitor | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 16.7 | 2.6 |
| Azithromycin | 1 | 0 | 0 | 1 |
| % | 3.6 | 0.0 | 0.0 | 2.6 |
| Benzathinebenzylpenicillin | 1 | 0 | 0 | 1 |
| % | 3.6 | 0.0 | 0.0 | 2.6 |
| Cefotaxime | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 16.7 | 2.6 |
| Ciprofloxacin | 0 | 1 | 0 | 1 |
| % | 0 | 20.0 | 0 | 2.6 |
| Coamoxiclav | 1 | 0 | 0 | 1 |
| % | 3.6 | 0.0 | 0.0 | 2.6 |
| Nitrofurantoin | 0 | 1 | 0 | 1 |
| % | 0 | 20.0 | 0 | 2.6 |
| Penicillins combinations with other antibacterials | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 16.7 | 2.6 |
| Sulfamethoxazole and trimethoprim | 1 | 0 | 0 | 1 |
| % | 3.6 | 0.0 | 0.0 | 2.6 |
| Tazobactam | 1 | 0 | 0 | 1 |
| % | 3.6 | 0.0 | 0.0 | 2.6 |

**Table 2f\_ Antibiotic Name\_ Fourth most recent\_ Medical Abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibiotic** | **KNH**  **n=19** | **NSIRH**  **n=4** | **TNH**  **n=5** | **Total**  **n=28** |
| Gentamicin | 5 | 0 | 1 | 6 |
| % | 26.3 | 0 | 20.0 | 21.4 |
| Amikacin | 4 | 0 | 1 | 5 |
| % | 21.1 | 0 | 20.0 | 17.9 |
| Meropenem | 3 | 0 | 0 | 3 |
| % | 15.8 | 0 | 0 | 10.7 |
| Metronidazole (oral.. | 0 | 2 | 0 | 2 |
| % | 0 | 50.0 | 0 | 7.1 |
| Vancomycin (parente.. | 1 | 1 | 0 | 2 |
| % | 5.3 | 25.0 | 0 | 7.1 |
| Amoxicillin and enz.. | 1 | 0 | 0 | 1 |
| % | 5.3 | 0 | 0 | 3.6 |
| Benzylpenicillin | 1 | 0 | 1 | 2 |
| % | 5.3 | 0 | 20.0 | 7.1 |
| Ceftazidime | 1 | 0 | 0 | 1 |
| % | 5.3 | 0 | 0 | 3.6 |
| Ceftriaxone | 0 | 1 | 0 | 1 |
| % | 0 | 25.0 | 0 | 3.6 |
| Ciprofloxacin | 1 | 0 | 0 | 1 |
| % | 5.3 | 0 | 0 | 3.6 |
| Clarithromycin | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 20.0 | 3.6 |
| Erythromycin | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 20.0 | 3.6 |
| Flucloxacillin | 1 | 0 | 0 | 1 |
| % | 5.3 | 0 | 0 | 3.6 |
| Levofloxacin | 1 | 0 | 0 | 1 |
| % | 5.3 | 0 | 0 | 3.6 |

**Table 2g\_ Antibiotic Name\_ Fifth most recent\_ Medical Abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibiotic** | **KNH**  **n=7** | **NSIRH**  **n=2** | **TNH**  **n=1** | **Total**  **n=10** |
| Flucloxacillin | 1 | 0 | 1 | 2 |
| % | 14.3 | 0 | 100.0 | 20.0 |
| Vancomycin (parenteral) | 2 | 0 | 0 | 2 |
| % | 28.6 | 0 | 0 | 20.0 |
| Amikacin | 1 | 0 | 0 | 1 |
| % | 14.3 | 0 | 0 | 10.0 |
| Amoxicillin and enzyme inhibitor | 0 | 1 | 0 | 1 |
| % | 0 | 50.0 | 0 | 10.0 |
| Betadine Mouthwash | 1 | 0 | 0 | 1 |
| % | 14.3 | 0 | 0 | 10.0 |
| Linezolid | 1 | 0 | 0 | 1 |
| % | 14.3 | 0 | 0 | 10.0 |
| Metronidazole (parenteral) | 0 | 1 | 0 | 1 |
| % | 0 | 50.0 | 0 | 10.0 |
| Piperacillin and enzyme inhibitor | 1 | 0 | 0 | 1 |
| % | 14.3 | 0 | 0 | 10.0 |

**Table 2h\_ Type and Dosage of Corticosteroids\_ Medical Abstraction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type/Dosage** | **KNH**  **n=13** | **NSIRH**  **n=2** | **TNH**  **n=6** | **Total**  **n=21** |
| Aldactone | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone 8mg Tds | 0 | 1 | 0 | 1 |
| % | 0.0 | 50.0 | 0.0 | 4.8 |
| Dexamethasone 0.2mg Iv Od | 0 | 0 | 1 | 1 |
| % | 0.0 | 0.0 | 16.7 | 4.8 |
| Dexamethasone 4mg IV TDS 3days | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone 8mg | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone 8mg Iv Tds | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone 8mg Tds | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone, 8mg, Tid, 2 Days | 0 | 1 | 0 | 1 |
| % | 0.0 | 50.0 | 0.0 | 4.8 |
| Dexamethasone, One Gram, I.V Twelve Hourly | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone (Dose Not Indicated) | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone 6mg | 0 | 0 | 1 | 1 |
| % | 0.0 | 0.0 | 16.7 | 4.8 |
| Iv Dexamethasone 60micrograms | 0 | 0 | 1 | 1 |
| % | 0.0 | 0.0 | 16.7 | 4.8 |
| Iv Methyl Prednisolone 500mg Od For 3days | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Maxtrol Eye Drops 1 Tds | 0 | 0 | 1 | 1 |
| % | 0.0 | 0.0 | 16.7 | 4.8 |
| Methylprednisolone | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Methylprednisone 40mg IV OD For 5days | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Prednisolone | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Prednisolone 15mg | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Prednisone 45mg AM | 1 | 0 | 0 | 1 |
| % | 7.7 | 0.0 | 0.0 | 4.8 |
| Dexamethasone,0.8 Mg | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 16.7 | 4.8 |
| Hydrocortisone 50mg Iv Tds | 0 | 0 | 1 | 1 |
| % | 0 | 0 | 16.7 | 4.8 |

**Table 3: Retrospective candida data from KNH between November 2017 to May 2022**

1. **Specimen: Blood**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Candida Species** | **1D** | **CASUALTY** | **CCU/ICU** | **Medicine** | **NICU/NBU** | **Paediatrics** | **Private Wing** | **Surgery** | **Total**  **n = 89** |
| C.albicans | 2 | 1 | 10 | 3 | 13 | 1 | 3 | 4 | **37** |
| **%** | 100 | 100 | 58.8 | 75 | 26.5 | 16.7 | 75.0 | 66.7 | **41.6** |
| C.auris | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | **3** |
| **%** | 0 | 0 | 17.7 | 0 | 0 | 0 | 0 | 0 | **3.4** |
| C.ciferri | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | **2** |
| **%** | 0 | 0 | 0 | 0 | 4.08 | 0 | 0 | 0 | **2.3** |
| C.lusitaniae | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | **1** |
| **%** | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | **1.1** |
| C.parapsilosis | 0 | 0 | 0 | 0 | 14 | 1 | 1 | 0 | **16** |
| **%** | 0 | 0 | 0 | 0 | 28.6 | 16.7 | 25 | 0 | **18.0** |
| C.pelliculosa | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | **7** |
| **%** | 0 | 0 | 0 | 0 | 14.3 | 0 | 0 | 0 | **7.9** |
| C.tropicalis | 0 | 0 | 3 | 1 | 2 | 0 | 0 | 0 | **6** |
| **%** | 0 | 0 | 17.7 | 25 | 4.1 | 0 | 0 | 0 | **6.7** |
| Candida spp | 0 | 0 | 1 | 0 | 11 | 3 | 0 | 2 | **17** |
| **%** | 0 | 0 | 5.9 | 0 | 22.5 | 50 | 0 | 33.3 | **19.1** |

1. **Specimen: Urine**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CandidaSpecies** | **CCU/ICU** | **NICU/NBU** | **Paediatrics** | **Private Wing** | **Total**  **n = 9** |
| C.auris | 1 | 0 | 0 | 0 | 1 |
| % | 33.3 | 0 | 0 | 0 | 11.1 |
| C.famata | 0 | 0 | 1 | 2 | 3 |
| % | 0 | 0 | 33.3 | 100.0 | 33.3 |
| C.gullermondii | 0 | 1 | 0 | 0 | 1 |
| % | 0 | 100.0 | 0 | 0 | 11.1 |
| C.lusitaniae | 2 | 0 | 2 | 0 | 4 |
| % | 66.7 | 0 | 66.7 | 0 | 44.4 |